Figurska Małgorzata, Matysik-Wożniak Anna, Adamiec-Mroczek Joanna, Dolar-Szczasny Joanna, Misiuk-Hojło Marta, Teper Sławomir, Święch-Zubilewicz Anna, Ulińska Magdalena, Rejdak Robert, Rękas Marek
Department of Ophthalmology, Military Institute of Medicine, The Central Clinical Hospital of the Ministry of National Defense, Warsaw, Poland.
Department of General Ophthalmology, Medical University of Lublin, Independent Public Teaching Hospital No. 1, Lublin, Poland.
Eur J Ophthalmol. 2020 May;30(3):586-594. doi: 10.1177/1120672119874598.
To report 12-month outcomes of a Polish National Treatment Program using aflibercept and ranibizumab in eyes with wet, age-related macular degeneration in routine clinical practice.
This was a non-randomized, retrospective, observational multicenter study. Anonymous data contained in the electronic Therapeutic Program Monitoring System were utilized in this study.
The study population consisted of 2828 eyes from 2718 patients. The median age was 76.0 [70.0, 81.0] years; 61.7% were female. Best corrected visual acuity increased from 58.86 [50.05, 69.95] letters to 65.1 [50.1, 73.9] letters (p < 0.001). The median change in best corrected visual acuity was 0.0 [-4.0, 12.2] letters: 2.9 [-2.9, 15.1] letters for treatment-naïve eyes and 0.0 [-4.0, 8.8] letters for those continuing treatment (p < 0.001). The median central retinal thickness was significantly reduced from 341.0 [281.0, 422.0] to 275.0 [221.0, 344.0] μm (p < 0.001). The median number of visits was 9.0 [8.0, 9.0]. The median number of injections was 7.0 [6.0, 8.0]: 8.0 [7.0, 8.0] for treatment-naïve eyes and 6.0 [5.0, 7.0] for those continuing treatment (p < 0.001).
Eyes treated as part of the Polish therapeutic program gained functional stability and morphological improvement. Treatment-naïve eyes showed the greatest functional benefit.
报告在常规临床实践中，使用阿柏西普和雷珠单抗治疗湿性年龄相关性黄斑变性的波兰国家治疗计划的12个月结果。
这是一项非随机、回顾性、观察性多中心研究。本研究使用了电子治疗计划监测系统中包含的匿名数据。
研究人群包括来自2718例患者的2828只眼。年龄中位数为76.0[70.0,81.0]岁；61.7%为女性。最佳矫正视力从58.86[50.05,69.95]字母提高到65.1[50.1,73.9]字母（p<0.001）。最佳矫正视力的中位数变化为0.0[-4.0,12.2]字母：初治眼为2.9[-2.9,15.1]字母，继续治疗的眼为0.0[-4.0,8.8]字母（p<0.001）。中心视网膜厚度中位数从341.0[281.0,422.0]显著降低至275.0[221.0,344.0]μm（p<0.001）。就诊次数中位数为9.0[8.0,9.0]。注射次数中位数为7.0[6.0,8.0]：初治眼为8.0[7.0,8.0]，继续治疗的眼为6.0[5.0,7.0]（p<0.001）。
作为波兰治疗计划一部分接受治疗的眼睛获得了功能稳定性和形态改善。初治眼显示出最大的功能益处。
